Michael Donmall

Michael Donmall

Auto-generated profile, based on publicly available information

Michael Donmall

National Drug Evidence Centre, University of Manchester, Manchester, UK

Research Focus & Metrics

Academic Career Length

42Years (1985-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2005 in Addiction
Verified
Journal Article
Closed access
PDF file
Petra MeierPetra Meier
Petra Meier
CBChristine Barrowclough
Christine Barrowclough
MDMichael C. Donmall
Michael C. Donmall

1 June 2006 in Drug and Alcohol Dependence
Verified
Journal Article
Closed access
Petra MeierPetra Meier
Petra Meier
MDMichael C. Donmall
Michael C. Donmall
PMPatrick McElduff
Patrick McElduff
CBChristine Barrowclough
Christine Barrowclough
RHRichard F. Heller
Richard F. Heller

22 March 2005 in Addiction
Verified
Journal Article
Closed access
PDF file
Petra MeierPetra Meier
Petra Meier
MDMichael C. Donmall
Michael C. Donmall
CBChristine Barrowclough
Christine Barrowclough
PMPatrick McElduff
Patrick McElduff
RHRichard F. Heller
Richard F. Heller

1 December 1999 in European Addiction Research
Verified
Journal Article
Closed access
PDF file
RSRoland Simon
Roland Simon
MDMichael Donmall
Michael Donmall
RHRichard Hartnoll
Richard Hartnoll
AKAna Kokkevi
Ana Kokkevi
AOA.W. Ouwehand
A.W. Ouwehand
JVJulian Vicente
Julian Vicente
Over the last decades inside and outside of Europe, treatment-based data have been used in epidemiological research on drugs and drug abuse. They offer information on hidden populations and allow to follow socially stigmatised behaviour. As this type of research can be done on rather low budgets, there are long-term projects run in many countries. Experts from the national systems in several EU member states have been working together to develop a common standard on the basis of the Pompidou Group (PG) Definitive Protocol. The items and basic definitions of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)/PG Treatment Demand Indicator Protocol are described, which plays an important role in the process of harmonisation of data collection for the EMCDDA. Implementation strategies are described, and future steps are discussed.

1 January 2015 in Health Technology Assessment
Verified
Journal Article
Open access
PDF file
KHKaren P Hayhurst
Karen P Hayhurst
MLMaria Leitner
Maria Leitner
LDLinda Davies
Linda Davies
RFRachel Flentje
Rachel Flentje
TMTim Millar
Tim Millar
JSJennifer Shaw
Jennifer Shaw
Background: The societal costs of problematic class A drug use in England and Wales exceed £15B; drug-related crime accounts for almost 90% of costs. Diversion plus treatment and/or aftercare programmes may reduce drug-related crime and costs.Objectives: To assess the effectiveness and cost-effectiveness of diversion and aftercare for class A drug-using offenders, compared with no diversion.Population: Adult class A drug-using offenders diverted to treatment or an aftercare programme for their drug use.Interventions: Programmes to identify and divert problematic drug users to treatment (voluntary, court mandated or monitored services) at any point within the criminal justice system (CJS). Aftercare follows diversion and treatment, excluding care following prison or non-diversionary drug treatment.Data sources: Thirty-three electronic databases and government online resources were searched for studies published between January 1985 and January 2012, including MEDLINE, PsycINFO and ISI Web of Science. Bibliographies of identified studies were screened. The UK Drug Data Warehouse, the UK Drug Treatment Outcomes Research Study and published statistics and reports provided data for the economic evaluation.Methods: Included studies evaluated diversion in adult class A drug-using offenders, in contact with the CJS. The main outcomes were drug use and offending behaviour, and these were pooled using meta-analysis. The economic review included full economic evaluations for adult opiate and/or crack, or powder, cocaine users. An economic decision analytic model, estimated incremental costs per unit of outcome gained by diversion and aftercare, over a 12-month time horizon. The perspectives included the CJS, NHS, social care providers and offenders. Probabilistic sensitivity analysis and one-way sensitivity analysis explored variance in parameter estimates, longer time horizons and structural uncertainty.Results: Sixteen studies met the effectiveness review inclusion criteria, characterised by poor methodological quality, with modest sample sizes, high attrition rates, retrospective data collection, limited follow-up, no random allocation and publication bias. Most study samples comprised US methamphetamine users. Limited meta-analysis was possible, indicating a potential small impact of diversion interventions on reducing drug use [odds ratio (OR) 1.68, 95% confidence interval (CI) 1.12 to 2.53 for reduced primary drug use, and OR 2.60, 95% CI 1.70 to 3.98 for reduced use of other drugs]. The cost-effectiveness review did not identify any relevant studies. The economic evaluation indicated high uncertainty because of variance in data estimates and limitations in the model design. The primary analysis was unclear whether or not diversion was cost-effective. The sensitivity analyses indicated some scenarios where diversion may be cost-effective.Limitations: Nearly all participants (99.6%) in the effectiveness review were American (Californian) methamphetamine users, limiting transfer of conclusions to the UK. Data and methodological limitations mean it is unclear whether or not diversion is effective or cost-effective.Conclusions: High-quality evidence for the effectiveness and cost-effectiveness of diversion schemes is sparse and does not relate to the UK. Importantly this research identified a range of methodological limitations in existing evidence. These highlight the need for research to conceptualise, define and develop models of diversion programmes and identify a core outcome set. A programme of feasibility, pilot and definitive trials, combined with process evaluation and qualitative research is recommended to assess the effectiveness and cost-effectiveness of diversionary interventions in class A drug-using offenders.Funding details: The National Institute for Health Research Health Technology Assessment programme.

1 January 2006 in Addiction Research & Theory
Verified
Journal Article
Closed access
TMTim Millar
Tim Millar
IGIslay Gemmell
Islay Gemmell
GHGordon Hay
Gordon Hay
RHRichard F. Heller
Richard F. Heller
MDMichael Donmall
Michael Donmall
This study investigates whether hypotheses about trends in the prevalence of problem drug use (PDU), prompted by capture--recapture based age-specific prevalence estimates, are corroborated by estimates of trends in incidence. Lag correction techniques were used to provide incidence estimates adjusted for the time-lag between onset of drug use and its first recorded treatment for heroin users seeking treatment in three areas of North West England between 1986 and 2000 (n = 4142). The incidence trends indicated geographical variation in the progress of heroin ‘epidemics’ in the areas studied and corroborated previously estimated prevalence rates that suggested PDU has passed its peak and is declining in some areas, but continues to increase in others. The lag correction method is capable of producing estimates that will improve our understanding of changes in the size and composition of the population targeted for drug misuse treatment and may provide a basis on which to forecast the direction of future trends.